Coherus Oncology, INC. (CHRS) — 10-Q Filings

All 10-Q filings from Coherus Oncology, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Coherus Swings to Profit on UDENYCA Divestiture, LOQTORZI Sales Up — Nov 6, 2025 Risk: medium
Coherus Oncology, Inc. reported a net income of $205.667 million for the nine months ended September 30, 2025, a significant increase from $79.203 million in th
Coherus Oncology Revenue Surges 209% on Toripalimab Sales — Aug 7, 2025 Risk: medium
Coherus Oncology, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $116.2 million, up from $37.5 million in th
Coherus BioSciences Q1 2025 10-Q Filed — May 12, 2025 Risk: low
Coherus BioSciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported Selling, General & Administrative Expense of $37.5 million f
Coherus BioSciences Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
Coherus BioSciences, Inc. filed its Q3 2024 10-Q report on November 6, 2024, for the period ending September 30, 2024. The company, formerly known as BioGeneric
Coherus BioSciences Q2 2024 10-Q: SG&A Expenses Detailed — Aug 8, 2024 Risk: medium
Coherus BioSciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported Selling, General & Administrative Expense of $112.2 million f
Coherus BioSciences Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
Coherus BioSciences, Inc. (CHRS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Coherus BioSciences reported financial results for the quarter end

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX